drugset / Trial / NCT05186363

Effectiveness of Seasonal Malaria Chemoprevention in Nampula Province, Mozambique: Type Two Hybrid Implementation Study

NCT05186363

Phase 4 Unknown 3156 enrolled Malaria Consortium
RandomizedParallel-groupSingle-blindPrevention

Summary

We describe a Type II hybrid effectiveness-implementation study design which evaluates the effects of a clinical intervention on relevant outcomes whilst collecting information on implementation. It is designed to determine feasibility and effectiveness of an innovative intervention, as well as the protective efficacy of the drugs used. The study consists of three components: 1) Conducting a cluster randomized controlled trial (cRCT) through household surveys establishing confirmed malaria cases in children; 2) Conducting a prospective cohort study to determine the chemoprevention efficacy of sulfadoxine-pyrimethamine and amodiaquine (SPAQ) and whether drug concentrations or parasite resistance influence the duration of protection; and 3) Conducting a resistance markers study in children 3-59 months to measure changes in resistance marker prevalence over time.

Timeline

Start
2022-01-08
Primary completion
2022-06-21
Completion
2023-12-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Sulfadoxine-pyrimethamine Small molecule
Comparator amodiaquine Other / unclassified

Indications